Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

LLY - ELI LILLY & Co


Close
765.55
-1.335   -0.174%

Share volume: 112,297
Last Updated: Mon 06 Jan 2025 08:30:05 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : -0.11%

PREVIOUS CLOSE
CHG
CHG%

$766.88
-1.34
-0.17%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
71%
Profitability 90%
Dept financing 25%
Liquidity 50%
Performance 70%
Company vs Stock growth
vs
Performance
5 Days
0.50%
1 Month
-5.41%
3 Months
-12.96%
6 Months
-14.82%
1 Year
24.91%
2 Year
115.46%
Key data
Stock price
$765.55
P/E Ratio 
124.27
DAY RANGE
$764.46 - $783.20
EPS 
$8.12
52 WEEK RANGE
$623.88 - $972.53
52 WEEK CHANGE
$24.91
MARKET CAP 
912.428 B
YIELD 
0.52%
SHARES OUTSTANDING 
950.426 M
DIVIDEND
$1.30
EX-DIVIDEND DATE
08/15/2024
NEXT EARNINGS DATE
10/30/2024
BETA 
0.96
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,976,759
AVERAGE 30 VOLUME 
$3,105,312
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax

Recent news